Understanding the intricate pathways modulating appetite and subsequent food intake is of particular importance considering the rise in obesity incidence across the globe. The serotonergic system, specifically the 5-HT2C receptor, has shown to be of critical importance in the regulation of appetite and satiety. The GHS-R1a receptor is another key receptor wellknown for its role in the homeostatic control of food intake and energy balance. We recently showed compelling evidence for an interaction between the GHS-R1a receptor and the 5-HT2C receptor in an in vitro cell line system heterologously expressing both receptors. Here, we investigated this interaction further. First, we show that the GHS-R1a/5-HT2C dimer-induced attenuation of calcium signalling is not due to coupling to GαS, as no increase in cAMP signalling is observed. Next, flowcytometry fluorescence resonance energy transfer (fcFRET) is used to further demonstrate the direct interaction between the GHS-R1a receptor and 5-HT2C receptor.
Introduction
The gastric-derived-peptide ghrelin acts as the endogenous ligand for the growth hormone secretagogue (GHS-R1a) receptor, which is also known as the ghrelin receptor 1, 2 .
Ghrelin is the only known gut-peptide exerting an orexigenic effect via the activation of the centrally expressed GHS-R1a receptor [3] [4] [5] [6] and has thus received much attention as an antiobesity drug target [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] . However, despite previous and ongoing drug development efforts, no weight-loss drugs that target the ghrelin receptor are currently on the market.
Initially, the GHS-R1a receptor was found to function as a homodimer 17, 18 . However, recently, the GHS-R1a receptor has also been shown to heterodimerize with other GPCRs involved in appetite regulation and food reward (for review see 19 ), including its truncated splice variant, the GHS-R1b receptor 18, [20] [21] [22] , the melanocortin 3 receptor (MC3) and the dopamine receptors (D1 and D2) [23] [24] [25] [26] [27] . Moreover, our lab has demonstrated compelling evidence for a functional interaction between the GHS-R1a and the 5-HT2C receptor 27 .
Interestingly, serotonergic signaling has since long been known to be involved in controlling food intake and to impact on satiety [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] . Individuals with normal regulated brain serotonin (5-hydroxytryptamine, 5-HT) levels are more easily satiated and display a better control over carbohydrate cravings inhibiting sugar intake more readily 39, 40 . Moreover, several drugs targeting the central serotonergic system, such as sibutramine and fenfluramine, have been specifically developed to induce satiety, or have been found to reduce food intake as a secondary effect, such as is the case for the 5-HT2B/2C agonist m-chlorophenylpiperazine (mCPP) 29, 37, 41, 42 . Unfortunately, none of these drugs have been without heart and pulmonary vasculature side-effects, or have been associated with a poor efficacy and other non-specific effects 33 .
The centrally expressed serotonin 2C (5-HT2C) receptor, in particular, has been shown to stimulate satiety via excitatory neurotransmission [29] [30] [31] [32] [33] [34] 43 . Indeed, a large amount of literature has validated the critical role played by the 5-HT2C receptor, which has substantiated this receptor as a viable target for the development of therapeutics in appetite control and weight
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6 management [30] [31] [32] [33] [34] [35] [36] [37] [38] . The recently approved 5-HT2C agonist lorcaserin is the first successful 5-HT2C receptor-targeting drug to reduce weight in the treatment of obesity [44] [45] [46] [47] .
Interestingly, the expression of the central 5-HT2C receptor 48, 49 corresponds with the expression profile of the neuronal circuits expressing the GHS-R1a receptor [50] [51] [52] , which is a first requirement for a physical interaction or dimerization. In addition, reciprocal interactions between the serotonin and ghrelin signalling pathways have been described previously. Indeed, administration of ghrelin to hypothalamic synaptosomes 53 was shown to inhibit 5-HT release, as was direct administration of ghrelin to hippocampal slices 54 . Similarly, recent data has demonstrated an increased serotonergic turnover in the amygdala and altered serotonin receptor mRNA levels (including the 5-HT2C receptor) in the amygdala and dorsal raphe, following acute central ghrelin administration 55 . Moreover, attenuated increases in acylatedghrelin were observed in response to an overnight fast in mice following pharmacological increases of brain serotonin levels or direct 5-HT2C receptor agonism 56 . In addition, direct administration of serotonin or the 5-HT2 receptor agonist 5-dimethoxy-4-iodoamphetamine (DOI) attenuated ghrelin's orexigenic effect in rats 57 . We hypothesize that this serotoninmediated attenuation of ghrelin signalling is mediated via crosstalk of the GHS-R1a receptor with the 5-HT2C receptor, potentially in a direct physical interaction. In line with this hypothesis, we have previously shown a functional interaction between the GHS-R1a and 5-HT2C receptor in vitro 27 , demonstrating an attenuated GHS-R1a signalling following co-expression of the 5-HT2C receptor, which reinforces the physiological relevance of the GHS-R1a/5-HT2C dimer.
However, although evidence for dimerization in vitro is compelling, in general the existence of GPCR dimers in native tissue has been questioned because of the paucity of reports demonstrating an interaction in vivo. In this study, we further investigate the interaction between the GHS-R1a and 5-HT2C receptor in relation to its function in appetite and we analyse the significance of the interaction of these two key receptors in vivo. Specifically, the co-localized expression of endogenous levels of these receptors in neuronal cultures is investigated using a recently described fluorescein-labelled ghrelin peptide tracer 58, 59 . Finally, the effects of specific ACS Paragon Plus Environment 7 5-HT2C receptor antagonism versus agonism on ghrelin's orexigenic effect is analysed in mice.
To our knowledge this is the first study to show functional relevance of a specific GHS-R1a and 5-HT2C receptor interaction on food intake behaviour in vivo. This data suggest the potential of combined GHS-R1a receptor antagonism and 5-HT2C receptor agonism as a novel therapeutic strategy in weight management.
Results and Discussion
Fluorescence energy transfer upon co-expression of the GHS-R1a receptor with the 5-HT2C receptor Heterodimerization of the GHS-R1a receptor with two variants of the 5-HT2C receptor was investigated using flow cytometry fluorescence energy transfer (FRET). To this end, Hek293A cells stably expressing the unedited 5-HT2C receptor or a partially edited isoform, 5-HT2C-VSVeGFP, both c-terminally fused with an enhanced green fluorescent fusion protein (eGFP), were transduced with lentiviral vectors expressing the GHS-R1a receptor C-terminally fused with a red fluorescent tag (lvGHS-R1a-TagRFP). The 5-HT2C receptor is prone to post-transcriptional RNA editing, which is the enzymatic conversion of an adenosine to inosine residues on 5 specific nucleotide positions (A, B, C, D, E) in the 2 nd intracellular loop and is thought to be associated with a reduced receptor functioning [60] [61] [62] [63] [64] [65] [66] . Therefore, we included both the unedited 5-HT2C receptor and the partly edited 5-HT2C-VSV receptor, which is the most abundantly expressed 5-HT2C receptor isoform in human brain. Indeed, the 5-HT2C-VSV receptor isoform is particularly abundant in the hypothalamus 65, 67 , where an increased 5-HT2C receptor editing has been linked with changes in feeding behaviour and fat mass 38, 66, 68 . Noteworthy increases in FRET levels, as addition, a similar attenuation of the GHS-R1a-mediated intracellular calcium mobilization upon co-expression of the 5-HT2C receptor was observed when the synthetic GHS-R1a ligand, MK0677, was used (Figure 2 B) . This is in line with our previous study and confirms the 5-HT2C receptor-mediated attenuation of GHS-R1a receptor signalling, which concurs the interaction between the two receptors 27 . Previously, it has been shown that the GHS-R1a receptor dimerizes with the dopamine D1 receptor leading to an enhanced dopamine induced c-AMP accumulation 24 and an attenuation of GHS-R1a-mediated calcium signalling 27 . This may suggest a dimer-induced switch in GHS-R1a receptor G-protein coupling from Gαq to Gαs, which has been previously suggested for neuronal GHS-R1a receptors expressed in neuropeptide Y (NPY) cells of the arcuate nucleus of the hypothalamus 69 . Thus, we set out to determine if the attenuated GHS-R1a receptor-mediated calcium mobilization observed here is due to a switch in G protein coupling from Gαq to Gαs. To this end, we measured cAMP increases in Hek293 cells expressing single receptors or co-expressing both the GHS-R1a and 5-HT2C receptors ( Figure 3 ). 
Co-localization of the 5-HT2C receptor and fluorescein-ghrelin staining ex vivo
Next, endogenous co-expression of the GHS-R1a receptor and the 5-HT2C receptor was investigated in rat neuronal cultures of the hypothalamus and hippocampus ( Figure 4 ). The hypothalamus is the main brain region integrating peripheral metabolic information controlling the homeostatic regulation of appetite and food intake 70, 71 . The hippocampus is a brain structure involved in learning and memory function and has recently been linked with food intake control 72 . In addition, the 5-HT2C receptor is strongly expressed in the hippocampus and on pro-opiomelanocortin (POMC) expressing neurons in the arcuate nucleus of the hypothalamus as well as in other hypothalamic regions 48, 49, 73, 74 . Moreover, a recent study by Bonn et al., demonstrates that the 5-HT2C receptor can also be found on NPY producing neurons 75, 76 , which was previously not recognized. In addition, a significant number of neurons in the hippocampus express the GHS-R1a receptor 51, 58, [77] [78] [79] as well as do most regions of the hypothalamus [50] [51] [52] . Specifically, in the arcuate nucleus, the GHS-R1a receptor is strongly expressed on NPY neurons, with 94% of the NPY neurons demonstrating GHS-R1a mRNA, but also on the POMC neurons , albeit only in 8% of the POMC neurons 80 . Here, we investigated the co-localization of endogenously expressed 5-HT2C receptor in primary cultured neurons of rat day 17 embryos (E17), using immunocytochemistry. Serotonergic neurons develop at E16 after which mucosal enterochromaffin cells containing the largest store of mammalian serotonin start to develop 81 . Therefore, neurons were cultured from rat pups at E17 to ensure 5-HT2C receptor expression. Central expression of the GHS-R1a receptor was analysed using a variation of a recently described method using fluorescein-ghrelin 82 , a novel strategy to detect specific GHS-R1a receptor expression 58 Figure 5A ). This is in line with previous findings from our lab and others demonstrating that a single administration of ghrelin causes an acute increase in food intake which is diminished over time 4, 83 . Interestingly, the significance of the ghrelin-induced increase in food intake was maintained after the 2 hr time point following SB242084-mediated 5-HT2C receptor antagonism (p<0.01), resulting in a ghrelin-mediated increase in food intake which was still apparent at 9 hours, while the 5-HT2C antagonist has no effects on food intake when administered on its own ( Figure 5A ). We hypothesize that the 5-HT2C receptor interacts with the GHS-R1a receptor following its activation by ghrelin, potentially via a dynamic dimerization, and attenuates ghrelin's orexigenic
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12 effect, which is in line with our in vitro findings (Figure2 and see 27 ). Specific 5-HT2C receptor antagonism maintains the significance of ghrelin's orexigenic effect following acute administration. In addition, the interaction on food intake following ghrelin and SB242084 coadministration, compared to ghrelin alone, are individually depicted in bar graphs and clearly visible at 8 and 24 hours after food placement, but not at 1hr ( Figure 5B, C, D) . At the 1 hr timepoint ghrelin's effect is still significant compared to control and co-administration of the 5-HT2C receptor antagonist here has no additional effect on food intake. Together, these data indicate that ghrelin-induced increases in food intake can be modulated via specific 5-HT2C
antagonism, resulting in a longer duration of ghrelin's orexigenic effect.
Specific 5-HT2C receptor agonism attenuates ghrelin's orexigenic effect in vivo
Finally, we analysed the effect of specific 5-HT2C receptor agonism, using lorcaserin, on ghrelin's orexigenic effect in vivo. To this end, cumulative food intake of male C57Bl/6 mice following subcutaneous administration of lorcaserin with and without intraperitoneal ghrelin was analysed ( Figure 6 ). Repeated measures analysis revealed a significant mean effect of treatment compared to vehicle (F(3,29) = 3.308; p = 0.034) but no significant interaction of time × treatment (F(5.046, 48.775)=0.956; p = 0.454). Again an initial significant increase in food intake was observed following acute treatment with ghrelin compared to vehicle, which lasted up to 2 hours, after which significance tapers off ( Figure 6A, B, C, D) . Interestingly, ghrelin's initial orexigenic effect was not observed when animals also received the 5-HT2C specific agonist, lorcaserin, at 3mg/kg. Indeed, when the 5-HT2C receptor is activated using lorcaserin, the acute orexigenic effect is completely blocked in the first 2 hours. Furthermore, no effect on food intake was observed with this sub-threshold dose of lorcaserin on its own ( Figure 6A ). At the 8h timepoint ghrelin's orexigenic effect compared to control is no longer observed, but the combination treatment actually has a significant decreased food intake compared to ghrelin, reinforcing the significantly inhibition on ghrelin's orexigenic effect by 5-HT2C receptor agonism ( Figure 6D ). determined. However, it is also possible that this interaction extends beyond the homeostatic hypothalamic regulation of food intake and may involve hedonic feeding behaviour. Indeed, recent studies have identified the ghrelinergic system as a key player in hedonic food intake behaviours, including the motivational drive to eat, the rewarding aspects of food intake and the stress-induced ingestion of palatable foods [84] [85] [86] [87] [88] [89] [90] [91] [92] . Interestingly, the 5-HT2C receptor has also been implicated in reward-related behaviours 93, 94 , which may explain some overlapping functionalities with the GHS-R1a receptor including involvement in the hedonic regulation of food intake. Another possibility to consider is that the interaction is not via a direct physical interaction but through an indirect mechanism mediated by the control both receptors have on the mesolimbic dopaminergic system, a key pathway for non-homeostatic feeding 95 . It has previously been shown that 5-HT2C receptor agonism has an inhibitory control on dopaminergic neurons in the ventral tegmental area (VTA) through the activation of GABAergic interneurons (for review, see 96 ). In addition, the GHS-R1a receptor is expressed on dopaminergic neurons in the VTA, enabling ghrelin to have a direct stimulatory effect on the mesolimbic dopaminergic system 97 . Indeed, detailed investigations into the potential interaction between GHS-R1a and 5-HT2C receptor signalling through the mesolimbic pathway are now warranted.
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Conclusion
Together, this study shows compelling evidence for a functionally relevant interaction between the GHS-R1a and 5-HT2C receptor. Pharmacological blockade of the 5-HT2C receptor enhances the duration of ghrelin-mediated increase in food intake in mice ( Figure 5 ), which is in
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line with the attenuation of ghrelin-mediated activation of the GHS-R1a in vitro when the 5-HT2C receptor is co-expressed (Figure 2 ). In addition, agonism of the 5-HT2C receptor, blocks ghrelin's orexigenic effect in mice (Figure 6 ), which may partly explain the satiety inducing effects of therapeutic doses of the 5-HT2C receptor specific agonist, lorcaserin. This data uncovers a novel mechanism for fine-tuning GHS-R1a receptor-mediated food intake via serotonergic activity.
These findings have important implications for the development of future pharmacological strategies in weight reduction. A more efficacious weight loss could potentially be achieved following the combined pharmacotherapeutic targeting of the ghrelinergic appetite signalling pathway and the 5-HT2C receptor-mediated induction of satiety, thereby enhancing specificity and reducing side effects. Indeed, a combined pharmacological treatment to target both the GHS-R1a and 5-HT2C receptor simultaneously might be a novel therapeutic approach in the treatment of eating disorders and obesity, and future investigations are warranted. In addition, a potential interaction of the GHS-R1a receptor and the 5-HT2C receptor in reward centers regulating the hedonic aspects of food intake, including the VTA, is likely to broaden the application potential of novel ghrelinergic and serotonergic pharmacotherapeutics.
Methods
Receptor ligands
Ligands were prepared as previously described 27 . Briefly, the endogenous ligand of the GHS- complete DMEM media supplemented with 300 ng/µl G418 as maintenance antibiotic, as previously described 27 . All cells were maintained at 37°C and 5% CO2 in a humidified atmosphere to a confluence of >85% after which the cells were resuspended and propagated to a lower density.
Transfection and lentiviral transduction
Stably transfected Hek293A cell lines were generated following Lipofectamine LTX plus reagent 
Calcium mobilization assay
Receptor-mediated changes in intracellular calcium (Ca 2+ ) were analysed as previously described 27 . Briefly, stably transfected cells were seeded in black 96-well microtiter plates at a density of 2.5 x 10 5 cells/ml (2.5 x 10 4 cells/well) and maintained for ~24hrs at 37°C in a humidified atmosphere containing 5% CO2. On the day of the assay, growth medium was 
Cumulative food intake
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Male C57Bl/6 mice (Harlan, UK) were housed per four in standard holding cages at the animal care facility of University College Cork. The holding room temperature (21±1 °C) and humidity (55±10%) were controlled under a 12-h light/dark cycle (lights on 7.00 AM, lights off 7.00 PM).
Water and food (2018S Teklad Global 18% Protein Rodent Diet) were available ad libitum throughout the study. The mice were habituated on three independent days to the experimental settings. Cumulative food intake studies were performed based on protocols described in previous studies ( The sub-threshold dose of 3 mg/kg (0.3 mg/ml) was selected for further experiments as no effect on food intake was observed using this dose for up to 8 hours. 
Statistical analysis
Statistical analyses were performed using SPSS software (IBM SPSS statistics 20, Chicago, IL, U.S.A.). For in vitro assays, significance was determined a two-way ANOVA at a significance level of p < 0.05. For food intake experiments, significant difference was determined with a general linear model repeated measurement combined with a one-way ANOVA with LSD post hoc test for each timepoint. If the data was non-spherical a Huynh-Feldt correction was applied. Graphs were expressed as mean ± SEM. Statistical significances were depicted as follows: * indicating p<0.05, ** indicating p<0.01 or *** indicating p<0.001. 
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